Pleura and peritoneum · 2025
The addition of collagenase to BromAc ® for the management of inoperable pseudomyxoma peritonei - in vitro results.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vici Carissa, Eapen Mathew, Narang Pooja, Morris David L
Аннотация
OBJECTIVES: Pseudomyxoma peritonei (PMP) is a rare peritoneal malignancy. BromAc ® is a novel therapeutic agent which has been developed to dissolve and facilitate the drainage of mucin as a palliative treatment for PMP; however, its effect is significantly reduced in patients with hard mucin. This study aimed to assess whether combining collagenase or cysteamine with BromAc ® would be more effective in dissolving hard mucin.
METHODS: This preclinical human in vitro study examined the effect of adding collagenase to BromAc ® on hard mucin samples when incubated at 37 °C over 24 h. The effect of cysteamine alone and in combination with collagenase and BromAc ® was also examined as a supplementary arm of this study. Five experiments were conducted with appropriate controls. Human hard mucin samples were sliced into equal fractions using a sterile surgical scalpel, weighed and noted. The leftover solid mucin was weighed at 0, 1, 3, 5, and 24 h post-treatment.
RESULTS: At 24 h post-treatment, all combinations with collagenase demonstrated almost 100 % dissolution of hard mucin. At 3 and 5 h post-treatment, only BromAc ® with collagenase at 250 μg/mL was found to be superior to BromAc ® alone. Combinations with cysteamine were not found to be effective.
CONCLUSIONS: This study provides promising evidence of the efficacy and synergistic effect of combining BromAc ® with collagenase to dissolve hard mucin. Further preclinical and clinical research should be undertaken to assess its safety and efficacy in the clinical setting.
METHODS: This preclinical human in vitro study examined the effect of adding collagenase to BromAc ® on hard mucin samples when incubated at 37 °C over 24 h. The effect of cysteamine alone and in combination with collagenase and BromAc ® was also examined as a supplementary arm of this study. Five experiments were conducted with appropriate controls. Human hard mucin samples were sliced into equal fractions using a sterile surgical scalpel, weighed and noted. The leftover solid mucin was weighed at 0, 1, 3, 5, and 24 h post-treatment.
RESULTS: At 24 h post-treatment, all combinations with collagenase demonstrated almost 100 % dissolution of hard mucin. At 3 and 5 h post-treatment, only BromAc ® with collagenase at 250 μg/mL was found to be superior to BromAc ® alone. Combinations with cysteamine were not found to be effective.
CONCLUSIONS: This study provides promising evidence of the efficacy and synergistic effect of combining BromAc ® with collagenase to dissolve hard mucin. Further preclinical and clinical research should be undertaken to assess its safety and efficacy in the clinical setting.